AV650-018: A two-part (double-blind followed by open-label), placebo-c
AV650-018: A two-part (double-blind followed by open-label), placebo-controlled,
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Tolperisone HC1
Who could take part
MS (type not specified)
Show the full criteria
Inclusion criteria
Inclusion: 1. Male or female subjects between 18 and 70 years of age (inclusive) Exclusion: 1. Subjects who have participated in another research study within 90 days of Screening
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To determine the long-term safety and tolerability of AV650 in subjects with spasticity associated with MS.
Loading reviews and guidelines…
Related trials
- Cryoneurolysis to treat pain in the context of spasticity
Phase 4 · Ongoing (inferred)
Still running
- A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spas
Phase 3 · Not yet recruiting
Still running
- Cannabis (THC vs. CBD) in Multiple Sclerosis
Phase 2 · Recruiting
Still running
- Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pa
Phase 2 · Recruiting
Still running
- Antibiotic strategy and asymptomatic bacteriuria in the context of int
Phase 3 · Ongoing
Still running
- A study to asses the effects of Nabiximols on spasticity associated wi
Phase 3 · Completed
No results found
History
Started
Aug 2007